Healthy Minds Canada/Pfizer Canada Workplace Depression Research Awards (Grants) 2016
Closes September 1, 2016
Eligible areas of research
- Any trial involving humans must be conducted in line with ICH guidelines and Canadian regulations (Health Canada).
- Clinical (involving humans)
- Outcomes/epidemiological research (eg. structured surveys, pharmaco-economics, disease management initiatives)
Non-eligible areas of research
- Basic Science I Fundamental (animal model, in-vivo I in-vitro)
- Studies involving the administration aiming to support the efficacy of a competitor drug or the use of a generic
- Proof of harm or otherwise highly invasive studies (unethical)
- Studies conflicting with global Pfizer-sponsored programs
- Mere repeat of existing studies (lack of innovation)
Areas of interest
- Research assessing the impact of rapid and early optimization of treatment on depression and level of functional improvement in workplace productivity, presenteeism and absenteeism
- Research assessing the impact of rapid and early optimization of treatment to minimize depression relapse in the workplace
- Research exploring the impact of rapid and early optimization of treatment to minimize the incidence of/mitigate the risks for depression in the workplace (eg. quality improvement research}.
The 2 awards (grants) are up to $25,000 each. Award funds are intended to be operating grants and must contribute towards the direct costs of the research program or project for which the funds are granted. Please note that the budget must be inclusive of institutional overhead where applicable; this amount shall not exceed 20% of the grant application budget. Please note that applicants may not receive a salary, a stipend, or an honorarium from the Award (grant).
Researcher Eligibility Criteria
- M.D., Ph.D. or Pharrn.D.
- Canadian citizen or landed immigrant with permanent Canadian residence
- Not receiving funding from other pharmaceutical industry for the research proposal that is being submitted
- Not receiving additional funding from the CIHR or other peer-reviewed Canadian funding agencies overlapping the scope of the research proposal that is being submitted
Please read. By applying, you accept the eligibility criteria
- Prior to the review, a pre-screening for completeness of applications & respect of eligibility criteria will be conducted. Incomplete applications and budget will not be considered
- Applications will be received via email at [email protected]
- Questions about the application process should be sent to [email protected]
- Submission will be a single (1) PDF sent to the above email address
- The research proposal should be no more than 10 pages (including graphs, tables, figures and excluding references, and no more than 2 manuscripts/published articles)
- Use standard 1inch margins, with font size of 10 to 12.
Include the following:
- Clear statement of purpose/aims, Primary and Secondary (if any) end points
- Timeline (Duration, Target start date, Target FSFV and LSLV dates, Target completion date, methodologies and available facilities, and resources)
- Other study details: Settings (single, multiple sites), Type (Phase l/11/111/IV), Inclusion/Exclusion criteria, Target subject enrollment, subject details (age, gender, etc.)
- Summary of relevant past work that is applicable to the project
- Summary of potential challenges and plans for addressing those obstacles
- Expected findings and potential impact of these findings (i.e., how your project will impact the health and quality of life of patients)
- Detailed statistical section: Sample size justification and proposed analysis of the data (a statistician should be able to verify calculations and choice of analyses)
- CV (Pl and possible Co-Pl or collaborators; CIHR format from common CV)
- Detailed budget (itemized)
- Study deliverables
- Target date to provide results to HMC and Pfizer
- Planned abstract and/or manuscript submission date (and targeted conference and/or journal)
- Applications will be reviewed by an independent review committee (RC).
About the Review Committee
- Exact composition to be determined jointly by HMC and Pfizer Canada
- RC chair is Dr. Glenda MacQueen, a psychiatrist from University of Calgary
- RC will be composed of clinical and research experts
Applications will be received via email at [email protected]
Questions about the application process should be sent to [email protected]